265 related articles for article (PubMed ID: 21502249)
1. Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration.
Ball R; Horne D; Izurieta H; Sutherland A; Walderhaug M; Hsu H
Pediatrics; 2011 May; 127 Suppl 1():S31-8. PubMed ID: 21502249
[TBL] [Abstract][Full Text] [Related]
2. Food and Drug Administration regulation and evaluation of vaccines.
Marshall V; Baylor NW
Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
[TBL] [Abstract][Full Text] [Related]
3. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
[TBL] [Abstract][Full Text] [Related]
4. Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).
Weaver J; Grenade LL; Kwon H; Avigan M
Dermatol Ther; 2009; 22(3):204-15. PubMed ID: 19453344
[TBL] [Abstract][Full Text] [Related]
5. Development and approval of vaccines in the United States.
Botstein P
Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
[TBL] [Abstract][Full Text] [Related]
6. Bolstering the FDA's drug-safety authority.
Schultz WB
N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
[No Abstract] [Full Text] [Related]
7. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
Nguyen M; Ball R; Midthun K; Lieu TA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
[TBL] [Abstract][Full Text] [Related]
8. The FDA and drug safety: a proposal for sweeping changes.
Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
[TBL] [Abstract][Full Text] [Related]
9. The Vaccine Safety Datalink: a model for monitoring immunization safety.
Baggs J; Gee J; Lewis E; Fowler G; Benson P; Lieu T; Naleway A; Klein NP; Baxter R; Belongia E; Glanz J; Hambidge SJ; Jacobsen SJ; Jackson L; Nordin J; Weintraub E
Pediatrics; 2011 May; 127 Suppl 1():S45-53. PubMed ID: 21502240
[TBL] [Abstract][Full Text] [Related]
10. Preventive medicines: vaccination, prophylaxis of infectious diseases, disinfectants.
Heininger U
Handb Exp Pharmacol; 2011; 205():317-37. PubMed ID: 21882119
[TBL] [Abstract][Full Text] [Related]
11. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
12. Editors' introduction: Vaccine safety throughout the product life cycle.
Salmon DA; Pavia A; Gellin B
Pediatrics; 2011 May; 127 Suppl 1():S1-4. PubMed ID: 21502245
[No Abstract] [Full Text] [Related]
13. US FDA review and regulation of preventive vaccines for infectious disease indications: impact of the FDA Amendments Act 2007.
Gruber MF
Expert Rev Vaccines; 2011 Jul; 10(7):1011-9. PubMed ID: 21806396
[TBL] [Abstract][Full Text] [Related]
14. How can you promote vaccine safety?
Miller ER; Iskander J; Pickering S; Varricchio F
Nursing; 2007 Apr; 37(4):58-63; quiz 63-4. PubMed ID: 17413371
[No Abstract] [Full Text] [Related]
15. The complicated task of monitoring vaccine safety.
Ellenberg SS; Chen RT
Public Health Rep; 1997; 112(1):10-20; discussion 21. PubMed ID: 9018282
[TBL] [Abstract][Full Text] [Related]
16. Policy developments in regulatory approval.
Temple R
Stat Med; 2002 Oct; 21(19):2939-48. PubMed ID: 12325110
[TBL] [Abstract][Full Text] [Related]
17. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
Kesselheim AS; Mello MM
Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
[TBL] [Abstract][Full Text] [Related]
18. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
19. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.
LaRussa PS; Edwards KM; Dekker CL; Klein NP; Halsey NA; Marchant C; Baxter R; Engler RJ; Kissner J; Slade BA
Pediatrics; 2011 May; 127 Suppl 1():S65-73. PubMed ID: 21502239
[TBL] [Abstract][Full Text] [Related]
20. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]